Table 3:
Association between lipid-lowering medication use and incident prostate cancer stratified by race and plasma total cholesterol, men in ARIC (1990–2012)
| Current use | # Incident prostate cancer |
Person- years | HR * | (95% CI) | HR † | (95% CI) | |
|---|---|---|---|---|---|---|---|
| Race | |||||||
| White Men | No | 343 | 51,661 | 1.0 | (Ref) | 1.0 | (Ref) |
| Yes | 198 | 27,602 | 0.93 | (0.77–1.13) | 0.94 | (0.78–1.15) | |
| Black Men | No | 170 | 15,290 | 1.0 | (Ref) | 1.0 | (Ref) |
| Yes | 89 | 5,930 | 1.21 | (0.90–1.62) | 1.27 | (0.95–1.71) | |
| P-interaction | 0.15 | 0.14 | |||||
| Total Cholesterol | |||||||
| Normal range (<5.2 nmol/L) |
No | 326 | 39,354 | 1.0 | (Ref) | 1.0 | (Ref) |
| Yes | 104 | 11,982 | 0.97 | (0.76–1.24) | 0.98 | (0.76–1.26) | |
| Borderline or elevated (≥5.2 nmol/L) |
No | 186 | 27,493 | 1.0 | (Ref) | 1.0 | (Ref) |
| Yes | 183 | 21,521 | 1.07 | (0.85–1.36) | 1.11 | (0.88–1.41) | |
| P-interaction | 0.38 | 0.44 | |||||
*
Adjusted for age, and joint categories of race and field center.
†
Adjusted for age, joint categories of race and field center, height, updated BMI, updated cigarette smoking status, updated diabetes status, updated aspirin use, and education level.